Adrian Newman-Tancredi

List of Publications by Citations

170 papers	7,385 citations	48 h-index	78 g-index
184 ext. papers	8,131 ext. citations	5.2 avg, IF	5.78 L-index

#	Paper	IF	Citations
170	The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 306, 954-64	4.7	414
169	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 791-804	4.7	361
168	Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. *Synapse*, **2000**, 36, 205-21	2.4	264
167	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. *European Journal of Pharmacology*, **1998**, 355, 245-56	5.3	180
166	Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. *Neuroscience*, **1998**, 84, 413-29	3.9	179
165	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 815-22	4.7	159
164	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 805-14	4.7	151
163	Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. *Neuropharmacology*, **2013**, 70, 338-47	5.5	142
162	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive	2.4	141
161	Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. *European Journal of Neuroscience*, **2000**, 12, 1079-95	3.5	132
160	Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. *Psychopharmacology*, **2011**, 216, 451-73	4.7	119
159	5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology*, **2014**, 231, 623-36	4.7	117
158	Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. *European Journal of Neuroscience*, **1999**, 11, 4419-32	3.5	112
157	Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 265-72	4.7	108
156	Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. *Neuropharmacology*, **2005**, 49, 996-1006	5.5	107
155	Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. *International Journal of Neuropsychopharmacology*, **2005**, 8, 341-56	5.8	106
154	The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. *Psychopharmacology*, **2001**, 156, 58-62	4.7	103

153	Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. *British Journal of Pharmacology*, **2009**, 156, 338-53	8.6	101
152	Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. *Molecular Pharmacology*, **1999**, 56, 1025-30	4.3	99
151	Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. *Molecular Pharmacology*, **2002**, 62, 578-89	4.3	98
150	Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies. *Behavioural Brain Research*, **2009**, 205, 360-6	3.4	95
149	Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. *Neuropharmacology*, **1996**, 35, 119-21	5.5	89
148	Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry. *Neuropharmacology*, **1997**, 36, 451-9	5.5	81
147	Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. *British Journal of Pharmacology*, **2010**, 160, 1929-40	8.6	78
146	Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. *Neuropsychopharmacology*, **2006**, 31, 1869-79	8.7	78
145	F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. *International Journal of Neuropsychopharmacology*, **2010**, 13, 1285-98	5.8	75
144	Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. *British Journal of Pharmacology*, **1997**, 120, 737-9	8.6	73
143	Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2002**, 365, 242-52	3.4	71
142	The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. *Current Opinion in Investigational Drugs*, **2010**, 11, 802-12		70
141	Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. *Neuropsychiatry*, **2011**, 1, 149-164	1.8	69
140	Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. *Neuropharmacology*, **2005**, 49, 135-43	5.5	69
139	F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. *European Neuropsychopharmacology*, **2010**, 20, 641-54	1.2	67
138	Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. *European Journal of Pharmacology*, **2006**, 535, 135-44	5.3	66
137	Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. *Molecular Pharmacology*, **2002**, 62, 590-601	4.3	62
136	Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. *European Journal of Pharmacology*, **2008**, 594, 32-8	5.3	61

135	Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2059-64	2.9	61
134	Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. *Neurobiology of Learning and Memory*, **2014**, 110, 72-80	3.1	58
133	Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. *European Journal of Pharmacology*, **2006**, 534, 63-70	5.3	58
132	Activity of serotonin 5-HT(1A) receptor biased agonists in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. *Neuropharmacology*, **2015**, 93, 52-67	5.5	55
131	High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. *Journal of Medicinal Chemistry*, **2007**, 50, 5024-33	8.3	55
130	Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. *Neuropsychopharmacology*, **2006**, 31, 1900-9	8.7	55
129	Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. *European Journal of Pharmacology*, **1997**, 319, 379-83	5.3	54
128	Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. *British Journal of Pharmacology*, **2006**, 149, 170-8	8.6	52
127	NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. *Experimental Neurology*, **2015**, 271, 335-50	5.7	51
126	Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. *Neuropsychopharmacology*, **1998**, 18, 395-8	8.7	51
125	S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 587-99	4.7	51
124	Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms. *Biochemical Pharmacology*, **1993**, 45, 1003-9	6	49
123	Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. *Brain Research*, **2005**, 1043, 32-41	3.7	48
122	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. *Pharmacological Reviews*, **2021**, 73, 310-520	22.5	48
121	F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. *British Journal of Pharmacology*, **2007**, 151, 266-77	8.6	47
120	Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. *Behavioural Pharmacology*, **2008**, 19, 145-52	2.4	46
119	Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. *European Journal of Pharmacology*, **2011**, 655, 46-51	5.3	44
118	Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. *Behavioural Pharmacology*, **2007**, 18, 103-18	2.4	42

117	Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1997**, 355, 682-8	3.4	41
116	Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 339, 2-8	4.7	40
115	S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors. *European Journal of Pharmacology*, **1996**, 307, 107-11	5.3	40
114	The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. *European Journal of Pharmacology*, **2008**, 592, 160-6	5.3	38
113	Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. *Psychopharmacology*, **2002**, 162, 168-77	4.7	38
112	Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. *Journal of Medicinal Chemistry*, **2001**, 44, 787-805	8.3	38
111	Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. *Molecular Pharmacology*, **2000**, 58, 1042-9	4.3	38
110	Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study. *Scientific Reports*, **2016**, 6, 26633	4.9	37
109	The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. *Journal of Neurochemistry*, **2010**, 114, 1323-32	6	37
108	[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 594-605	8.8	37
107	F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. *British Journal of Pharmacology*, **2007**, 151, 253-65	8.6	37
106	In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. *Psychopharmacology*, **2012**, 221, 261-72	4.7	36
105	F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. *British Journal of Pharmacology*, **2007**, 151, 237-52	8.6	35
104	WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. *European Journal of Pharmacology*, **2007**, 574, 15-9	5.3	35
103	Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. *Journal of Medicinal Chemistry*, **2007**, 50, 865-76	8.3	35
102	Native rat hippocampal 5-HT1A receptors show constitutive activity. *Molecular Pharmacology*, **2007**, 71, 638-43	4.3	34
101	The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. *Neuropharmacology*, **2015**, 97, 306-11	5.5	33
100	Activity of Serotonin 5-HT Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties. *ACS Chemical Neuroscience*, **2018**, 9, 1040-1050	5.7	32

99	In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2006**, 373, 441-50	3.4	32
98	Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. *Neuroscience Research*, **2010**, 66, 135-40	2.9	31
97	Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. *Neuropharmacology*, **2007**, 52, 1106-13	5.5	31
96	Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. *Neuropsychopharmacology*, **2001**, 25, 410-22	8.7	31
95	Characterizing the differential roles of striatal 5-HT auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. *Experimental Neurology*, **2017**, 292, 168-178	5.7	30
94	Divergent effects of the ßbiasedß5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task. *British Journal of Pharmacology*, **2015**, 172, 2532-43	8.6	30
93	Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2014**, 387, 545-57	3.4	27
92	Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. *Journal of Medicinal Chemistry*, **2002**, 45, 165-76	8.3	27
91	Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimerß disease: A post-mortem study with PET radiopharmaceuticals. *Neuropharmacology*, **2016**, 109, 88-95	5.5	27
90	Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1998**, 357, 205-17	3.4	26
89	S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 903-20	4.7	26
88	The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements. *Neuropharmacology*, **2016**, 105, 651-660	5.5	26
87	Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. *Current Opinion in Investigational Drugs*, **2007**, 8, 539-54		26
86	Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT receptor selective agonist, NLX-112 in mouse models of pain. *Neuropharmacology*, **2017**, 125, 181-188	5.5	25
85	Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2003**, 368, 188-99	3.4	25
84	Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. *Brain Research*, **2001**, 920, 41-54	3.7	25
83	Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists. *Frontiers in Physiology*, **2014**, 5, 205	4.6	24
82	F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. *European Journal of Pharmacology*, **2009**, 620, 27-35	5.3	24

81	Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors. *Cellular Signalling*, **2002**, 14, 829-37	4.9	24
80	Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1034-42	4.7	24
79	Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. *Behavioural Pharmacology*, **2009**, 20, 303-11	2.4	23
78	Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635. *British Journal of Pharmacology*, **2001**, 132, 518-24	8.6	23
77	Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms. *Neuropharmacology*, **2001**, 40, 57-64	5.5	23
76	Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT receptor agonist. *Journal of Pharmacy and Pharmacology*, **2017**, 69, 1178-1190	4.8	22
75	The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine. *Pharmacology Biochemistry and Behavior*, **2009**, 92, 363-9	3.9	22
74	5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. *British Journal of Pharmacology*, **2009**, 158, 232-42	8.6	22
73	Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. *European Journal of Pharmacology*, **2008**, 581, 37-46	5.3	22
72	Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. *International Journal of Neuropsychopharmacology*, **2008**, 11, 293-307	5.8	22
71	Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. *Current Pharmaceutical Design*, **2015**, 21, 3725-31	3.3	22
70	Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. *Naunyn-Schmiedebergts Archives of Pharmacology*, **2007**, 376, 93-105	3.4	21
69	Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. *Psychopharmacology*, **2007**, 193, 45-54	4.7	21
68	Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. *European Journal of Pharmacology*, **2001**, 428, 177-84	5.3	21
67	Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging. *Journal of Nuclear Medicine*, **2012**, 53, 969-76	8.9	20
66	Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. *Neuropharmacology*, **2005**, 49, 963-76	5.5	19
65	The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. *European Journal of Pharmacology*, **2000**, 394, 47-50	5.3	19
64	Activation of 5-HT postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 99, 109832	5.5	19

63	Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	18
62	ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility. *British Journal of Pharmacology*, **2014**, 171, 973-84	8.6	18
61	A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease. *CNS Neuroscience and Therapeutics*, **2014**, 20, 930-4	6.8	18
60	Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. *Neuropsychopharmacology*, **1999**, 21, 61S-67S	8.7	18
59	F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT receptor agonist for PET neuroimaging. *Brain Structure and Function*, **2018**, 223, 2973-2988	4	17
58	NLX-112, a highly selective 5-HT receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT receptors, respectively. *Brain Research*, **2018**, 1688, 1-7	3.7	17
57	Anti-aggressive effects of the selective high-efficacy biased 5-HT receptor agonists F15599 and F13714 in male WTG rats. *Psychopharmacology*, **2016**, 233, 937-47	4.7	17
56	h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. *British Journal of Pharmacology*, **2003**, 138, 1077-84	8.6	17
55	Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1999**, 359, 447-53	3.4	17
54	Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. *European Journal of Pharmacology*, **1995**, 280, 225-9	5.3	17
53	In vivo biased agonism at 5-HT receptors: characterisation by simultaneous PET/MR imaging. *Neuropsychopharmacology*, **2018**, 43, 2310-2319	8.7	16
52	Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds. *European Journal of Pharmacology*, **2008**, 597, 34-8	5.3	16
51	From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery. *Current Topics in Medicinal Chemistry*, **2019**, 19, 2393-2420	3	16
50	The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. *Neuropharmacology*, **2020**, 167, 107997	5.5	15
49	Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT receptor biased agonists. *Experimental Neurology*, **2018**, 302, 155-168	5.7	15
48	Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine. *European Journal of Pharmacology*, **1997**, 327, 247-56	5.3	15
47	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT Receptor-Biased Agonists with Robust Antidepressant-like Activity. *Journal of Medicinal Chemistry*, **2019**, 62, 2750-2771	8.3	14
46	Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model. *Journal of Psychopharmacology*, **2019**, 33, 1456-1466	4.6	14

45	[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2000**, 361, 569-72	3.4	14
44	The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study. *European Journal of Pharmacology*, **1999**, 384, 111-21	5.3	14
43	Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization. *Pharmacology Biochemistry and Behavior*, **2002**, 71, 589-98	3.9	13
42	Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. *Psychopharmacology*, **2005**, 177, 373-80	4.7	13
41	Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase. *European Journal of Pharmacology*, **2001**, 424, 13-7	5.3	13
40	F-F13640 PET imaging of functional receptors in humans. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 220-221	8.8	13
39	S32212, a novel serotonin type 2C receptor inverse agonist/2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 750-64	4.7	12
38	Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. *Neuropharmacology*, **1998**, 37, 769-80	5.5	12
37	Serotonin 5-HT Receptor Biased Agonists Display Differential Anxiolytic Activity in a Rat Social Interaction Model. *ACS Chemical Neuroscience*, **2019**, 10, 3101-3107	5.7	11
36	Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents. *European Journal of Pharmacology*, **2011**, 672, 83-7	5.3	11
35	Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. *Behavioural Brain Research*, **2009**, 203, 288-95	3.4	11
34	Serotonin 5-HT Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats. *ACS Chemical Neuroscience*, **2019**, 10, 3108-3119	5.7	11
33	Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference. *Cellular Signalling*, **2011**, 23, 58-64	4.9	10
32	Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons. *Journal of Neuroscience Research*, **2000**, 59, 740-9	4.4	10
31	Effects of the Serotonin 5-HT Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats. *Neurochemical Research*, **2018**, 43, 1035-1046	4.6	9
30	Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model. *Behavioural Pharmacology*, **2011**, 22, 599-606	2.4	9
29	F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. *European Journal of Pharmacology*, **2009**, 607, 74-83	5.3	8
28	F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2007**, 375, 241-50	3.4	8

27	[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum. *Neuropharmacology*, **2000**, 39, 1111-3	5.5	8
26	[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors. *Neuropharmacology*, **1995**, 34, 1693-6	5.5	8
25	Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. *Pharmacology*, **2005**, 75, 63-8	2.3	7
24	An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2000**, 361, 221-3	3.4	7
23	The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. *Parkinsonism and Related Disorders*, **2020**, 78, 151-157	3.6	7
22	Enhanced aggressive phenotype of Tph2 knockout rats is associated with diminished 5-HT receptor sensitivity. *Neuropharmacology*, **2019**, 153, 134-141	5.5	6
21	Bell-shaped agonist activation of 5-HT receptor-coupled G G-proteins: Receptor density-dependent switch in receptor signaling. *Cellular Signalling*, **2019**, 63, 109383	4.9	6
20	Pharmacological characterisation of the 5-HT1A serotonin receptor using the agonist [3H]8-OH-DPAT, and the antagonist [3H]spiperone. *Biochemical Society Transactions*, **1992**, 20, 145S	5.1	6
19	Pharmacological MRI to investigate the functional selectivity of 5-HT receptor biased agonists. *Neuropharmacology*, **2020**, 172, 107867	5.5	6
18	Discovery of Novel pERK1/2- or Arrestin-Preferring 5-HT Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. *Journal of Medicinal Chemistry*, **2020**, 63, 10946-10971	8.3	6
17	Translating biased agonists from molecules to medications: Serotonin 5-HT receptor functional selectivity for CNS disorders. *Pharmacology & Therapeutics*, **2021**, 107937	13.9	6
16	Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535. *Annals of the New York Academy of Sciences*, **1998**, 861, 263-4	6.5	5
15	The selective 5-HT receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress. *Psychopharmacology*, **2021**, 238, 2249-2260	4.7	5
14	Activation of somatodendritic 5-HT autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test. *Psychopharmacology*, **2019**, 236, 1171-1185	4.7	5
13	Perspectives for therapy of treatment-resistant depression. *British Journal of Pharmacology*, **2021**,	8.6	5
12	NLX-101, a cortical 5-HT receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition. *Brain Research*, **2021**, 1765, 147493	3.7	5
11	Differential ligand efficacy at h5-HT1A receptor-coupled G-protein subtypes: a commentary. *International Congress Series*, **2003**, 1249, 101-117		3
10	Identification of the 5-HT serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease. *Neurobiology of Disease*, **2021**, 152, 105278	7.5	3

9	The 5-HT receptor as a serotonergic target for neuroprotection in cerebral ischemia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 109, 110210	5.5	3
8	Towards in vivo imaging of functionally active 5-HT receptors in schizophrenia: concepts and challenges. *Translational Psychiatry*, **2021**, 11, 22	8.6	3
7	NLX-112, a highly selective 5-HT receptor agonist: Effects on body temperature and plasma corticosterone levels in rats. *Pharmacology Biochemistry and Behavior*, **2018**, 165, 56-62	3.9	3
6	[F]F13640, a 5-HT Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. *Frontiers in Neuroscience*, **2021**, 15, 622423	5.1	2
5	The selective 5-HT receptor agonist NLX-112 displays anxiolytic-like activity in mice. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2021**, 395, 149	3.4	1
4	Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline. *Behavioural Pharmacology*, **2021**, 32, 652-659	2.4	1
3	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinsonʼs Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. *Journal of Parkinsonʼs Disease*, **2021**, 11, 1257-1269	5.3	1
2	Dissecting the contribution of 5-HT auto- and heteroreceptors in sucrose overconsumption in mice.. *Biomedicine and Pharmacotherapy*, **2022**, 148, 112699	7.5	0
1	Biased 5-HT receptor agonists F13714 and NLX-101 differentially affect pattern separation and neuronal plasticity in rats after acute and chronic treatment.. *Molecular and Cellular Neurosciences*, **2022**, 120, 103719	4.8	0